<< Read Full Article
<< Read Full Article
Vertex Falls on Cystic Fibrosis Drug Study
- Loading Comments...
Another small study of Vertex Pharmaceuticals' (VRTX Quote) experimental cystic fibrosis drug released Monday showed that the drug, VX-770, improved lung function and was safe.
Shares of Vertex fell 3% to $24.91, however, because results from the latest VX-770 study were not entirely consistent with the previous study released last March.
Despite some questions raised about the latest VX-770 study, Vertex said Monday that it intends to work with U.S. and European regulators to design a pivotal phase III study of VX-770 to begin in 2009. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,337.05 | 1,095.94 | 2,183.73 | 34.23 |
Oil *
72.45
|
|
UP
51.08
|
UP
4.01
|
UP
10.74
|
UP
0.31
|
10 Yr
3.42%
SPDR Gold
110.84
|
|
+0.50%
|
+0.37%
|
+0.49%
|
+0.91%
|
Data delayed 20 minutes |


Connect with TheStreet